Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors.
Stefanini B, Bucci L, Santi V, Reggidori N, Rampoldi D, Lani L, Granito A, Sangiovanni A, Cabibbo G, Farinati F, Campani C, Foschi FG, Svegliati-Baroni G, Raimondo G, Gasbarrini A, Mega A, Biasini E, Sacco R, Morisco F, Caturelli E, Vidili G, Azzaroli F, Giannini EG, Rapaccini GL, Brunetto MR, Masotto A, Nardone G, Di Marco M, Magalotti D, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group.
Stefanini B, et al. Among authors: giannini eg.
Dig Liver Dis. 2022 Nov;54(11):1563-1572. doi: 10.1016/j.dld.2022.07.003. Epub 2022 Jul 27.
Dig Liver Dis. 2022.
PMID: 35906166